what federal pharmacy rules allow today
What FDA rules let a pharmacy do with MOTS-c
FDA held a July 23-24, 2026 meeting about rule 503A. That code covers medicine made for a patient named on the prescription. The meeting wasn't a ruling.
What FDA has and hasn't decided
MOTS-c began as a substance for research, not as medicine for you. FDA hasn't approved it for medical use in the United States. You won't find an approved form over the counter.
FDA held a public meeting in July 2026. A group of experts discussed MOTS-c as a pharmacy ingredient. The meeting gave you no new access. FDA has published no result from it.
This page explains the broad federal rules for you. It also tells you what comes before a pharmacy fills a drug. The rules alone don't settle your own case. Nothing here sells or supplies MOTS-c.
What MOTS-c must have before pharmacy use
MOTS-c is a 16-amino-acid peptide. A peptide is a short chain used to make part of a protein. Mitochondria, the cell parts that supply energy, hold its DNA directions. MOTS-c lacks FDA drug approval for any use [1][17].
Rule 503A covers medicine a pharmacy makes for a patient named on the prescription. The rule doesn't allow every raw ingredient. An ingredient must qualify in one of three ways.
First, federal law may recognize an official drug-book standard for the ingredient. That tells your pharmacist what the raw ingredient must contain. Second, a drug with FDA approval may already use it. Third, FDA may place the ingredient on its 503A list [17].
FDA can review an ingredient after a request [17]. A group of experts may then advise FDA. MOTS-c was on the July 2026 review list [19]. The meeting itself doesn't allow your pharmacy to use it.
What rules 503A and 503B let pharmacies do
Federal law gives pharmacies two ways to make drugs from raw ingredients [17]. Section 503A covers a drug prepared after an individual prescription. Section 503B covers FDA-registered centers that make larger batches.
FDA inspects the centers that make batches [17]. For your own drug, the pharmacy starts with your prescription. An allowed batch may instead go to your doctor's office before anyone is named. Neither rule lets a pharmacy use any raw ingredient.
Both rules limit raw ingredients. Federal law may recognize a drug-book standard for one. A drug with FDA approval may already contain it. Or FDA may put it on the proper list [17].
If none applies, FDA reviews the ingredient first [17]. A group of experts may give advice. Approval for a ready-made drug is a separate matter. MOTS-c is neither approved nor listed for you now [17][19].
What FDA experts discussed in July 2026
FDA published the subjects for its July meeting. MOTS-c was named on that list. The group met on July 23-24, 2026 [19].
Experts discussed whether to advise adding MOTS-c to the 503A ingredient list. FDA staff had proposed not to add it. The list decides which raw materials can go into drugs prepared after an individual prescription. The review covered plain MOTS-c and MOTS-c acetate, which is a salt form. Neither form is approved for you.
The list also names BPC-157, TB-500, and KPV [19]. Each substance gets a separate review. One result can't settle another for you.
The meeting was only a discussion. It was not a listing decision [19]. It did not change your access.
The group advises FDA. FDA doesn't have to follow its advice [19]. Remember that when you read online claims.
MOTS-c remains a peptide used for research. Your care has no FDA-approved MOTS-c. As of September 2026, FDA hasn't published a record of the experts' votes. Nothing FDA has published says your pharmacy can use MOTS-c.
What online claims FDA hasn't confirmed
Some online claims go beyond FDA's pages. A rule change isn't final until FDA acts. The July meeting took place, but FDA has published no result and no date for a final choice. Those claims can't tell you what access is lawful.
In early 2026, one report discussed roughly 14 peptides. The report said some peptides placed in a higher-risk group in 2023 might be moved out. It didn't identify who set that label or what the change would mean. Sellers also said some peptides were removed in April 2026.
FDA's page, current as of April 22, 2026, no longer lists MOTS-c in that higher-risk group; it shows the request to add MOTS-c as withdrawn [17][19]. FDA gives no date for that change, so the April claim is still unconfirmed. FDA's safety concerns still sit beside the entry, and FDA hasn't said what the change means for a pharmacy. Neither claim makes MOTS-c available to you.
One event is firm. FDA published the July 2026 meeting list [19], and the meeting took place. FDA staff had recommended against adding MOTS-c. The vote record isn't out, and you don't know how FDA will rule.
What must happen before a pharmacy makes a drug
A compounded medicine is a drug a pharmacy mixes for a patient's needs. Lawful pharmacy mixing begins after a licensed prescriber reviews your health [18]. You may meet in person or by video [18]. The prescriber decides if the drug fits your care.
A video visit doesn't loosen the ingredient rules [18]. You still need a true doctor-patient relationship and a valid prescription. A video call can't replace a full review of your health.
If the use is lawful, the prescriber writes your prescription [18]. A state-licensed 503A pharmacy may make medicine for you by name. A registered 503B center may make certain batches for doctors' offices. The raw ingredient must still be allowed [18].
FDA may flag a raw ingredient for major safety risks. A 503A pharmacy then can't use that ingredient for normal patient prescriptions. These are broad rules, not advice for you. This page doesn't offer or supply MOTS-c [18].
What today's rules mean for MOTS-c access
Has FDA approved MOTS-c as medicine?
No. MOTS-c is a peptide used for research, not approved care. It has no approved use for you [1][17].
No form or amount for people has approval. MOTS-c appeared on FDA's July 2026 meeting list [19]. That meeting didn't change today's rules for you.
Can a pharmacy make MOTS-c for you now?
Not under the normal rule. Section 503A covers medicine tied to an individual prescription. A raw ingredient needs an official drug-book standard, prior use in an FDA-approved drug, or a place on the allowed list [17].
MOTS-c doesn't qualify in any of those ways now [17][19]. You'd also need a licensed prescriber and a valid prescription [18]. Those steps can't make an unlisted raw ingredient lawful for you.
Where does MOTS-c stand under rule 503A?
MOTS-c isn't on FDA's list for drugs tied to an individual prescription. It also lacks FDA drug approval [17][19]. Experts looked at it during the July 23-24, 2026 meeting, after FDA staff advised against adding it. FDA hasn't released their votes [19]; nothing it has published permits pharmacy use.